AKBA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin

akebia therapeutics inc (AKBA) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AKEBIA THERAPEUTICS INC (AKBA)
\

Related News

No related news articles were found.

akebia therapeutics inc (AKBA) Related Businessweek News

No Related Businessweek News Found

akebia therapeutics inc (AKBA) Details

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

324 Employees
Last Reported Date: 03/26/19
Founded in 2007

akebia therapeutics inc (AKBA) Top Compensated Officers

CEO, President & Director
Total Annual Compensation: $957.1K
Senior VP, CFO & Treasurer
Total Annual Compensation: $539.6K
Senior VP & Chief Medical Officer
Total Annual Compensation: $604.1K
Senior VP & Chief Business Officer
Total Annual Compensation: $424.0K
Compensation as of Fiscal Year 2018.
akebia therapeutics inc
Akebia Therapeutics, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-04-2019 03:00 PM

Akebia Therapeutics, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-04-2019 03:00 PM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: John P. Butler, CEO, President & Director.

Akebia Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Announces Full Enrollment of its Global Phase 3 INNO VATE Studies for Vadadustat

Akebia Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2019. For the quarter, the company reported collaboration revenue of $72,666,000 against $45,930,000 a year ago. Operating loss was $75,969,000 against $24,498,000 a year ago. Net loss was $72,421,000 against $23,418,000 a year ago. Net loss per basic and diluted share was $0.62 against $0.48 a year ago. The company announced full enrollment of its global Phase 3 INNO VATE studies for vadadustat, that it has bolstered its commercial capabilities with the addition of Dell Faulkingham as Senior Vice President, Chief Commercial Officer, and appointed Steven K. Burke, M.D., as Senior Vice President, Chief Medical Officer. Dr. Burke will join the company from Proteon Therapeutics, Inc., where he has been Senior Vice President and Chief Medical Officer since 2006. The first quarter marked the achievement of another important milestone for Akebia with the announcement of positive top-line results from two Phase 3, active-controlled, pivotal studies evaluating vadadustat in Japanese patients with anemia due to chronic kidney disease (CKD), stated John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. The company also announced the completion of enrollment in global Phase 3 INNO 2VATE studies evaluating vadadustat for the treatment of anemia due to CKD in dialysis-dependent CKD subjects. With the addition of Dell Faulkingham to executive team, and have strengthened the commercial capabilities and believe that well positioned to execute on revenue growth strategies for Auryxia.

Akebia Therapeutics, Inc. Announces Management Changes

Akebia Therapeutics, Inc. announced full enrollment of its global Phase 3 INNO2VATE studies for vadadustat, that it has bolstered its commercial capabilities with the addition of Dell Faulkingham as Senior Vice President, Chief Commercial Officer, and appointed Steven K. Burke, M.D., as Senior Vice President, Chief Medical Officer. Steven K. Burke, will succeed Rita Jain, who informed the company of her plans to step down from her position as Senior Vice President, Chief Medical Officer effective June 17, 2019 to pursue other opportunities. Dr. Burke will join the company from Proteon Therapeutics, Inc., where he has been Senior Vice President and Chief Medical Officer since 2006. Prior to joining Proteon, Dr. Burke served as Senior Vice President of Medical and Regulatory Affairs at Genzyme Corporation, where he worked from 2001 to 2006. From 1994 to 2001, Dr. Burke held roles at GelTex Pharmaceuticals, Inc. including Vice President of Clinical Research and Medical Director, and before that he held positions at Glaxo, Inc. Dell Faulkingham joins the company with more than 20 years of commercial experience across a broad range of specialty pharmaceutical categories. His experience includes commercial leadership roles with Biogen Inc., where he held multiple positions of increasing responsibility, most recently serving as Senior Vice President and Head, U.S. Multiple Sclerosis (MS) Franchise. Mr. Faulkingham also recently served as Vice President, Head of U.S. MS Marketing and Field Operations at Biogen. Prior to joining Biogen, Mr. Faulkingham held several roles with Takeda Pharmaceuticals.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

AKBA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKBA.
View Industry Companies
 

Industry Analysis

AKBA

Industry Average

Valuation AKBA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.0x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AKEBIA THERAPEUTICS INC, please visit www.akebia.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.